TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04588376

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer comparison feedback monthly
Description: Monthly emailed data on performance for guideline-concordant use of antibiotics for three acute upper respiratory tract infections either at the clinician and clinic levels or at the clinic level only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer comparison feedback monthly
Description: Monthly emailed data on performance for guideline-concordant use of antibiotics for three acute upper respiratory tract infections either at the clinician and clinic levels or at the clinic level only
Study: NCT03970967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study: NCT04847167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group
Description: The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
Study: NCT04097925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descovy
Description: Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
Study: NCT00510406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin hydrochloride
Description: Alphablocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin hydrochloride
Description: Alphablocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin hydrochloride
Description: Alphablocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin hydrochloride
Description: Alphablocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin succinate
Description: antimuscarinic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin succinate
Description: antimuscarinic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin succinate
Description: antimuscarinic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin succinate
Description: antimuscarinic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin succinate
Description: antimuscarinic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin succinate
Description: antimuscarinic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01396486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Children with bipolar spectrum disorders ages 6-12 will receive treatment with omega-3 fatty acids. Study subjects may be randomized to receive 3000mg (6 500mg capsules) of omega-3 fatty acids for the duration of the study. Omega-3 fatty acid capsules are in the form of Nordic Naturals brand, ProOmega Junior, which contains 325mg EPA and 225mg DHA per two capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Children with bipolar spectrum disorders ages 6-12 will receive treatment with omega-3 fatty acids. Study subjects may be randomized to receive 3000mg (6 500mg capsules) of omega-3 fatty acids for the duration of the study. Omega-3 fatty acid capsules are in the form of Nordic Naturals brand, ProOmega Junior, which contains 325mg EPA and 225mg DHA per two capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inositol
Description: Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inositol
Description: Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
Study: NCT02147431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.~Each treatment period will be followed by a hypoglycaemic clamp

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.~Each treatment period will be followed by a hypoglycaemic clamp.
Study: NCT00816894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: 6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
Study: NCT03058809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oncopheresis
Description: Oncopheresis is a type of apheresis incorporating an extracorporeal blood circuit and a filter to separate circulating tumor cells from normal blood components.
Study: NCT04568629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advice from the PiPS-B14 prognostic tool
Description: Participants were informed that prognostic advice came from the PiPS-B14 prognostic tool. PiPS-B14 is a validated prognostic algorithm that has been shown to be as accurate as an agreed multi-professional survival estimate.~Participants were further informed that in a previous study the PiPS-B14 risk categories for predicting two-week survival were as accurate as a doctor's or a nurse's prediction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advice from another clinician
Description: Participants were informed that prognostic advice came from another clinician.~Doctors were told that advice was from a nurse, whereas nurses or other types of HCPs were told that advice was from a doctor.
Study: NCT00303329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox available as 125 mg, 250 mg or 500 mg tablets
Study: NCT03770936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: Candesartan 8 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: ramipril 1.25 mg/day
Study: NCT01749436

Intervention type: OTHER
Intervention: Lung ultrasound imaging examinations
Description: Lung ultrasound examinations performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis related to laparoscopic procedures.
Study: NCT04493736

Intervention type: BEHAVIORAL
Intervention: MHSAFE app recording
Description: Participants are asked a series of questions to elicit their feelings and emotions as part of an audio recorded interview along with their normal therapy session.
Study: NCT01664585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training group
Description: The 60-minute training sessions include a few mobilization techniques for upper neck. In detail, three different exercises concentrated on postural and motor control will be taught during the first two training sessions. Progressively, two additional exercise movements aiming at postural and motor control will be taught in the next session. After eight weeks, two muscle strength exercises utilising therapeutic rubber band will be included into the program. The aim of the rubber band exercises is eventually to achieve the load of 80% of maximal voluntary contraction. The participants in the training group are also instructed to increase their amount of physical activity progressively according to the current physical activity recommendations.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0) and the participants in control group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
Study: NCT01351415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60 or 75 milligram per meter square (mg/m\^2) on Day 1 every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 60 or 75 milligram per meter square (mg/m\^2) on Day 1 every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 IV over 10 minutes on Day 1 every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 IV over 10 minutes on Day 1 every 21 days.
Study: NCT01775995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation-CBT Intervention + Usual Care
Description: The intervention combines meditation and standard-of-care CBT strategies for chronic low back pain. It consists of eight weekly 2-hour group sessions guided by trained instructors. In addition to session attendance, experimental participants are asked to practice meditation at home at least 6 days/week, 30 minutes/day during the 26-week study.~Control participants will be offered the intervention after completing the study.~All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Alone
Description: All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
Study: NCT00652964

Intervention type: DEVICE
Intervention: CPAP
Description: CPAP treatment for patients with congenital central hypoventilation syndrome
Study: NCT02525835

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dietary Sodium
Description: Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dietary Sodium
Description: Participants will be randomized to a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
Study: NCT01742182

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Light exposure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light exposure
Study: NCT04117100

Intervention type: PROCEDURE
Intervention: Polypectomy or myotomy
Description: Advanced therapeutic endoscopy can replace surgery for treatment of benign and malign GI diseases and the aim of this registry-based study to improve quality related to advanced therapeutic endoscopy because the trial will provides a quantitative method to assess advanced therapeutic practise at the CHUM and may identify practices of low quality (possible intervention) or high quality (desired). Advanced therapeutic endoscopy procedures included for this registry-based study are EMR, ESD, Assessment of polypectomy quality for colorectal adenomas/polyps, Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC), and Per Oral endoscopic Myotomy (POEM).
Study: NCT02740114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: 266 mg injected on each side of the wound at the end of surgery before wound closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pill Diary
Description: Participants complete a pill diary every day for 30 days after hospital discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pill Diary
Description: Participants complete a pill diary every day for 30 days after hospital discharge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Questionnaire
Description: Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Questionnaire
Description: Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
Study: NCT02551484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurements using NIRS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurements using NIRS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TCPO2 measurements

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TCPO2 measurements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-minute walk test
Study: NCT00758966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine 60 mg
Description: Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 32 mg and fluoxetine 60 mg
Description: Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone SR 32 mg
Description: Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy.
Study: NCT01820234

Intervention type: OTHER
Group type: OTHER
Intervention: In-person dermatology evaluation
Description: Every patient will be evaluated by an in person dermatologist present at the screening.

Intervention type: OTHER
Group type: OTHER
Intervention: Store-and-forward teledermatology evaluation
Description: Every patient will be evaluated online via a store and forward teledermatology modality.
Study: NCT03234257

Intervention type: DEVICE
Group type: OTHER
Intervention: UF-ultrasound
Description: the carotid plaque stability by UF in order to improve the stroke prediction in case of asymptomatic stenosis. A UF-ultrasound approach is a non-irradiating, easily accessible, and low cost technique
Study: NCT03999749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 4 induction doses (during the 2 treatment cycles) at a dose of 1 mg/kg intravenously (IV) every 3 weeks, 4 times during the 12-week induction period, concurrent with nivolumab at 3 mg/kg administered at the same interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (3 mg/kg) will be administered IV on Days 1 and 22 of each 42-day induction treatment cycle. Nivolumab will continue to be administered IV at 240 mg flat dose every 2 weeks; i.e., at Days 1, 15, 29, 43, 57, and 71 of the 84-day treatment cycle for the first maintenance cycle until week 24, then nivolumab will be administered at 480 mg flat dose every 4 weeks to a maximum of 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Administered intravenously for each 42-day induction treatment cycle. After 12 weeks of therapy, starting at Week 13, subjects enter the maintenance phase. Tocilizumab will be administered intravenously every 6 weeks during the first 84 day maintenance treatment cycle only at 4 mg/kg
Study: NCT01617447

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Aripiprazole
Description: administered orally once daily
Study: NCT03163472

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary brachial plexus block with 10 mL oof local anaesthetic
Description: patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary brachial plexus block with 30 ml of local anaesthetic
Description: patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
Study: NCT00548470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 1-2 mg/day
Study: NCT02217254

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System
Study: NCT04150770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Study: NCT03244683

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ensure Surgical
Description: Subjects randomized to the intervention arm will consume two Ensure Surgical for 5-7 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition counseling
Description: All study subjects will be provided with nutrition counseling at the time of study enrollment.

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition counseling
Description: All study subjects will be provided with nutrition counseling at the time of study enrollment.

Intervention type: OTHER
Group type: OTHER
Intervention: Low-intensity exercise therapy
Description: Patients randomized to the intervention arm will also be provided with verbal and written instructions for light resistance training. The exercises will be performed at home during the preoperative study period.
Study: NCT04302636

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Description: The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
Study: NCT03787134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: working memory and attention
Description: Behavioral tests of working memory and attention
Study: NCT01959295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: 200 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASP2151 placebo
Description: once daily
Study: NCT03059797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
Study: NCT01869985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1104 / Mulex Tab. and Airtal Tab.
Description: HCP1104 / Eperisone plus Aceclofenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP1104 / Mulex Tab. and Airtal Tab.
Description: HCP1104 / Eperisone plus Aceclofenac
Study: NCT00683579

Intervention type: DRUG
Intervention: Early Treatment with HAART
Description: HAART with possibility of de-intensification

Intervention type: OTHER
Intervention: No treatment
Description: No treatment. For group 2, participants do not yet meet DHHS guidelines. For group 4, treatment is not initiated due to unwillingness or providers' expectation of poor adherence.

Intervention type: OTHER
Intervention: No treatment
Description: No treatment. For group 2, participants do not yet meet DHHS guidelines. For group 4, treatment is not initiated due to unwillingness or providers' expectation of poor adherence.

Intervention type: DRUG
Intervention: HAART Treatment - standard care
Description: Initiation of HAART per DHHS guidelines, i.e. starting treatment and CD4+ T cells less than 350 cells/mm3 or HIV RNA \>100,000 copies/ml
Study: NCT00754546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arformoterol tartrate
Description: 15 mcg in two ml solution administered via nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Normal Saline
Description: Normal saline was nebulized.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycle Exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cycle Exercise
Study: NCT04358952

Intervention type: DIAGNOSTIC_TEST
Intervention: Global Longitudinal Strain
Description: Electrocardiogram with measure of the Global Longitudinal Strain to evaluate myocardiac dysfunction